Keynote Financial Services LLC Buys 191,215 Shares of Senseonics Holdings, Inc. $SENS

Keynote Financial Services LLC grew its stake in Senseonics Holdings, Inc. (NYSE:SENS) by 1,120.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 208,285 shares of the company’s stock after buying an additional 191,215 shares during the period. Keynote Financial Services LLC’s holdings in Senseonics were worth $99,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. CTC Alternative Strategies Ltd. bought a new position in shares of Senseonics in the first quarter valued at approximately $31,000. IFP Advisors Inc grew its stake in Senseonics by 120.9% in the 1st quarter. IFP Advisors Inc now owns 47,500 shares of the company’s stock valued at $31,000 after buying an additional 26,000 shares during the last quarter. Elite Life Management LLC bought a new position in Senseonics in the 2nd quarter worth $36,000. State of Wyoming bought a new position in Senseonics in the 1st quarter worth $40,000. Finally, Cambridge Investment Research Advisors Inc. lifted its position in Senseonics by 679.9% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 289,919 shares of the company’s stock worth $190,000 after acquiring an additional 252,745 shares during the last quarter. Institutional investors own 12.36% of the company’s stock.

Senseonics Stock Up 5.3%

Shares of SENS stock opened at $6.33 on Tuesday. Senseonics Holdings, Inc. has a one year low of $5.00 and a one year high of $28.00. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. The stock has a fifty day moving average price of $8.37 and a 200 day moving average price of $9.84. The stock has a market cap of $257.85 million, a P/E ratio of -48.69 and a beta of 0.79.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Stifel Nicolaus started coverage on Senseonics in a research note on Tuesday, October 21st. They issued a “hold” rating and a $9.00 price objective on the stock. HC Wainwright lifted their price target on Senseonics to $18.50 and gave the stock a “buy” rating in a research report on Thursday, November 6th. TD Cowen cut their price target on Senseonics from $25.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Lake Street Capital raised Senseonics to a “strong-buy” rating in a research report on Thursday, July 17th. Finally, Barclays reaffirmed an “overweight” rating and set a $31.00 target price (up previously from $1.50) on shares of Senseonics in a research report on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $22.70.

Insider Transactions at Senseonics

In other Senseonics news, CFO Frederick T. Sullivan purchased 5,415 shares of the business’s stock in a transaction on Friday, November 7th. The stock was purchased at an average price of $5.88 per share, for a total transaction of $31,840.20. Following the completion of the purchase, the chief financial officer directly owned 157,028 shares in the company, valued at approximately $923,324.64. This trade represents a 3.57% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Douglas A. Roeder acquired 15,000 shares of the firm’s stock in a transaction on Friday, November 7th. The shares were bought at an average cost of $5.83 per share, for a total transaction of $87,450.00. Following the completion of the acquisition, the director directly owned 99,727 shares of the company’s stock, valued at approximately $581,408.41. This represents a 17.70% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 3.60% of the stock is currently owned by company insiders.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.